Imaging Clinical Research Organization (CRO) Market to Grow with a CAGR of 8.26% through 2030

Growing number of clinical trials and adoption of automation in imaging process to drive the imaging clinical research organization (CRO) market in the forecast period, 2026-2030.

According to TechSci Research report, “Imaging Clinical Research Organization (CRO) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2030”, the Global Imaging Clinical Research Organization (CRO) Market was valued at USD 5.51 billion in 2024 and is expected to reach USD 8.87 billion by 2030 with a CAGR of 8.26% during the forecast period. The rising number of clinical trials, increasing prevalence of rare diseases, and extensive research and development are the primary factors driving the demand for the global imaging clinical research organization (CRO) market. The surge in the number of biotechnology and pharmaceutical industries, increased research and development investments for developing new drugs to treat various diseases, rising healthcare expenditure, and rising automation of imaging process are expected to influence the market demand. Also, the rise in adoption of growing number of strategic acquisitions and mergers by the market players are also a key factor for increasing the growth of the imaging clinical research organization (CRO) market, globally.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Imaging Clinical Research Organization (CRO) Market"

The global imaging clinical research organization (CRO) market is segmented into services offered, imaging modality, clinical trial phase, application, end user, regional distribution and company. 

Based on Clinical Trial Phase, Phase 3 clinical trials show the fastest growth. This acceleration is largely due to the increasing number of late-stage trials that require comprehensive imaging endpoints to support regulatory approval and market entry. Phase 3 studies typically involve large patient populations across multiple geographies, making imaging critical for consistent and objective assessment of treatment efficacy and safety. The growth is supported by the surge in oncology, neurology, and cardiovascular trials where imaging biomarkers are pivotal for primary or secondary endpoints. For example, in cancer drug development, imaging-based criteria like RECIST (Response Evaluation Criteria in Solid Tumors) are often used to quantify tumor response, while in neurology, volumetric MRI is frequently used to monitor disease progression in Alzheimer’s and multiple sclerosis studies. According to ClinicalTrials.gov, the number of Phase 3 trials incorporating advanced imaging endpoints has increased by over 30% in the past five years.

Based on region, Asia Pacific shows the fastest growth in the Global Imaging Clinical Research Organization (CRO) market, driven by a combination of expanding healthcare infrastructure, rising investments in clinical trials, and a growing patient pool for diverse therapeutic areas. Countries such as China, India, South Korea, Japan, and Australia are emerging as major hubs for imaging-based clinical research due to lower trial costs, faster patient recruitment rates, and government initiatives to attract multinational pharmaceutical and biotechnology companies. According to the World Health Organization (WHO), Asia accounts for nearly 60% of the global population, providing a vast and diverse subject base, which is crucial for multi-phase imaging trials. In addition, regional governments are actively supporting clinical research growth. For instance, China’s National Medical Products Administration (NMPA) has streamlined regulatory approval processes for clinical trials, while India’s Department of Biotechnology (DBT) funds research programs integrating imaging in oncology, neurology, and cardiology studies. The number of registered clinical trials in the Asia Pacific region has surged in recent years — ClinicalTrials.gov data shows that between 2018 and 2023, trials in Asia grew by more than 50%, with a significant share involving imaging modalities like MRI, PET-CT, and ultrasound.

Major operating companies operating in Global Imaging Clinical Research Organization (CRO) Market are:

• Laboratory Corporation of America Holdings
• IXICO PLC
• ICON plc
• The Micron Group
• Medpace Holdings, Inc.
• Radiant Sage LLC
• Biomedical Systems Corporation
• Worldcare Clinical, LLC
• Imaging Endpoints LLC
• Parexel International Corporation

Download Sample Report

Customers can also request for 10% free customization on this report.

“The growing demand for advanced imaging solutions in clinical trials is significantly driving the growth of the global Imaging Clinical Research Organization (CRO) market. As pharmaceutical, biotechnology, and medical device companies continue to focus on accelerating drug development and improving trial outcomes, the adoption of imaging-based endpoints for enhanced accuracy and regulatory compliance is becoming increasingly essential. Furthermore, the rising complexity of clinical studies and the need for standardized imaging data, supported by stringent regulatory requirements and growing emphasis on evidence-based results, are propelling the market forward. As the healthcare and life sciences industry evolves, the integration of AI-driven imaging analytics, cloud-based data management, and innovative imaging modalities will be key to improving efficiency, reducing trial timelines, and ensuring quality assurance. With ongoing advancements in digital technologies, expanding applications across oncology, neurology, and cardiovascular research, and increasing demand from emerging markets, imaging CROs are poised to play a pivotal role in shaping the future of global clinical research and drug development,” said Mr. Karan Chechi, Research Director at TechSci Research, a research-focused management consulting firm.

“Imaging Clinical Research Organization (CRO) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Services Offered (Imaging Acquisition and Protocol Development, Application Design, Image Collection and Quality Control, Digital Image Conversion, Support and Maintenance, Others), By Imaging Modality (Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Others), By Clinical Trial Phase (Phase 1, Phase 2, Phase 3), By Application (Oncology, Neurology, Cardiovascular, Ophthalmology, Others), By End User (Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Academic & Research Institutions, Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of global imaging clinical research organization (CRO) market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global imaging clinical research organization (CRO) market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com